Acusphere Stock

Acusphere EV/EBIT

EV/EBIT (Enterprise Value to EBIT) of Acusphere (ACUS) as of Jul 26, 2026.

EV/EBIT

-0.00

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Acusphere is 2026 -0.00 . EV/EBIT (Enterprise Value to EBIT) of Acusphere was 2025 - . It decreases by % lower compared to the previous year.

The Acusphere EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2005
0.00 base
Jan 1, 2006
0.00 base
Jan 1, 2007
0.00 base
Jan 1, 2008
0.00 base
Jan 1, 2009 (e)
0.00 base
Jan 1, 2010 (e)
0.00 base
Jan 1, 2011 (e)
0.00 base
Jan 1, 2012 (e)
0.00 base
YEARPRICE-TO-EBIT
2012 est -
2011 est -
2010 est -
2009 est -
2008 -
2007 -
2006 -
2005 -
2004 -
2003 -
2002 -
2001 -
2000 -
1999 -
1998 -
Access this data via the Eulerpool API
Get Free API Key

Acusphere Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Acusphere's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Acusphere's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Acusphere's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Acusphere grows earnings faster than its peers.

Acusphere Stock analysis

What does Acusphere do? Acusphere Inc is a US-American company that was founded in 1993. It specializes in the development and marketing of advanced pharmaceuticals and therapeutic platforms in the fields of cardiology and pulmonology. The company is based in Lexington, Massachusetts and currently employs about 30 employees. The history of Acusphere goes back to the discovery of a new class of pharmaceutical agents, called microspheres. These spherical particles have a diameter of only a few micrometers and can have the ability to bind various therapeutic agents and release them in a targeted manner in the body. Acusphere has developed several innovative products and technologies based on these microspheres in recent years. One focus of the company is the development of therapies for patients with cardiovascular diseases such as heart failure or coronary artery disease. Another research area of ​​the company is the development of therapies for patients with lung diseases such as COPD or asthma. The business model of Acusphere is mainly based on the discovery and marketing of new drugs and therapies. In order to achieve these goals, the company works closely with leading scientific institutions and invests a significant portion of its budget in research and development. Acusphere is divided into several business areas, each of which includes different products and technologies. One of the most important business areas is the development of drugs for the treatment of cardiovascular diseases. An example of this is the drug EchoSphere, which was developed based on microspheres and is able to improve the oxygen supply to the heart muscle. Another important business area of ​​Acusphere is the development of products for the treatment of lung diseases such as COPD and asthma. For this purpose, the company has developed several new technologies that allow targeted delivery of medication to the lungs and its effects there. One of these technologies is the so-called Solutol technology, which allows medication to be concentrated in the alveoli of the lungs while avoiding unwanted side effects. In recent years, Acusphere has developed a number of innovative products and technologies that have great market potential due to their high efficacy and tolerability. The company is making every effort to bring these products to the market as quickly as possible and make a significant contribution to improving healthcare. Acusphere is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acusphere stock

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Acusphere since 2006 – with annual values, charts, and detailed analysis.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Acusphere

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Acusphere